Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-09-30 (marketbeat.com)
Saratoga Research & Investment Management Sells 5,060 Shares of Biogen Inc. (NASDAQ:BIIB)
Saratoga Research & Investment Management lessened its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 3.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 157,791 shares of the biotechnology c
Read more
2024-09-11 (finmarket.ru)
Finam raised its target price for Biogen shares to $241.7
Finam raised its target price for Biogen Inc. shares. to $241.7 per share, which implies a growth potential of 20.4% over a 12-month horizon, according to a commentary by the leading analyst of the investment company Zarina Saidova.
Read more
2024-06-26 (aktiencheck.de)
Biogen shares: Investors beware! ()
Biogen shares: Investors beware! () | aktiencheck.de
Read more
2024-06-10 (tijd.be)
5 favorite shares of Joost Olbrechts: 'This share is betting on the Next AI wave'
The investment advisor chooses shares in Brussels, Zurich, Wall Street and Singapore.
Read more
2024-02-23 (ariva.de)
Minimal price discount for the Biogen share (€205.4700)
Biogen shares are currently unremarkable on the US stock market. The paper is currently trading at $222.34.
Read more
2024-01-28 (marketbeat.com)
Illinois Municipal Retirement Fund Grows Stake in Biogen Inc. (NASDAQ:BIIB)
Illinois Municipal Retirement Fund lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 68,391 shares of the biotechnology company's stock after acquiring an
Read more
2023-11-14 (finmarket.ru)
Investbank
Investment bank ``Sinara'' maintains ``hold'' rating for Tesla shares with outlook
Read more
2023-09-28 (marketbeat.com)
Eudaimonia Partners LLC Has $1.46 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Eudaimonia Partners LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 150.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,114 shares of the biotechnology company's stock after purchasing
Read more
2023-08-07 (forbes.com)
Pharma Earnings Reports Are Moving The Markets And AI Shakes Up The Emerging Tech Space - Forbes AI Newsletter August 5th
Subscribe to the Forbes AI newsletter to stay in the loop and get AI-backed investing insights, the latest news and more delivered directly to your inbox every weekend.
Read more
2023-05-16 (finanznachrichten.de)
Biogen share price down today
In US securities trading, Biogen's shares are trading lighter at the moment. The security is currently trading at $308.21. The Biogen share has today on the US stock exchange
Read more
2023-05-12 (nasdaq.com)
3 Reasons to Buy Biogen Stock (and 1 to Sell)
Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago, but after controversy surrounding its approval, the stock ultimately gave back much of those gains. Nowadays, it has become a b
Read more
2021-06-08 (onvista.de)
Morphosys: Approval of Biogen's Alzheimer's drug also provides confidence for the German biotech stock - shares continue to recover
Morphosys shares are continuing their recovery thanks to good news from the industry environment. The US company Biogen has received approval for its Alzheimer's drug aducanumab.
Read more